skip to Main Content

A Blood-Based Assay for Diagnosis of Early-Stage Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
In this study including 39 patients with histologically proven and clearly resectable pancreatic ductal adenocarcinoma (PDAC) (recruited from the NEONAX trial) and 15 patients with benign pancreatic disease (intraductal papillary-mucinous neoplasms, IPMN) as controls, researchers tested a new biomarker combination for early PDAC, consisting of thrombospondin-2 (THBS2), CA19-9 and circulating tumor DNA (ctDNA) analysis.

Read more . . . 

Back To Top